Jennifer M. Suga

Hematology Oncology | Hematology | Oncology

975 Sereno Dr
Vallejo, CA 94589

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial.

Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial.

Journal: JAMA surgery

Published: July 01, 2026

Optimizing Cancer Care Delivery Through High-Functioning Teams: Results of Implementing the 4R Oncology Model in Lung and Breast Cancers.

Optimizing Cancer Care Delivery Through High-Functioning Teams: Results of Implementing the 4R Oncology Model in Lung and Breast Cancers.

Journal: JCO oncology practice

Published: May 30, 2026

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1.

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 26, 2026

Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0.

Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 03, 2026

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0.

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 03, 2026

Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in U.S. patients with unresectable stage III NSCLC following concurrent chemoradiation.

Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in U.S. patients with unresectable stage III NSCLC following concurrent chemoradiation.

Journal: Future oncology (London, England)

Published: December 23, 2025

Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.

Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 02, 2025

Real-world outcomes of multimodal treatment for pleural mesothelioma: A retrospective study in a high-volume integrated regional center.

Real-world outcomes of multimodal treatment for pleural mesothelioma: A retrospective study in a high-volume integrated regional center.

Journal: JTCVS open

Published: September 24, 2025

The role of targetable biomarker alterations in overall survival for non-small cell lung cancer (NSCLC) in a large integrated health system.

The role of targetable biomarker alterations in overall survival for non-small cell lung cancer (NSCLC) in a large integrated health system.

Journal: Journal of thoracic disease

Published: May 21, 2025

A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohort.

A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohort.

Journal: Therapeutic advances in medical oncology

Published: April 04, 2025

Financial Hardship Among Patients With Early-Stage Colorectal Cancer.

Financial Hardship Among Patients With Early-Stage Colorectal Cancer.

Journal: JAMA network open

Published: September 17, 2024

Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial.

Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial.

Journal: JNCI cancer spectrum

Published: August 16, 2024

Showing 1-12 of 36

Last Updated: 09/26/2026